Medications for the treatment of sleep disorders: An overview

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 3, Issue 3, 2001, Pages 118-125

  Pagel, J F ^a,b   Farnes, Bennett L ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Rocky Mountain Sleep Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 20344372479     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v03n0303     Document Type: Article

References (46)

1. Reite ML, Nagel KE, Ruddy JR. The Evaluation and Management of Sleep Disorders. Washington, DC: American Psychiatric Press; 1990
2. American Sleep Disorders Association. Thorpy MJ, ed. The International Classification of Sleep Disorders: Diagnosis and Coding Manual. Lawrence, Kansas: Alien Press; 1990
3. Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine. 2nd ed. Philadelphia, Pa: WB Saunders; 1994
4. Wysowski DK, Baum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 thought 1989. Arch Intern Med 1991; 151:1779-1783
5. Sateia MJ, Doghramji K, Hauri PJ, et al. Evaluation of chronic insomnia. Sleep 2000;23:243-314
6. Miller MM. Nonselective and selective benzodiazepine receptor agonists: where are we today? Sleep 2000;23(suppl 1):S39-S47
7. Aldrich MS. Automobile accidents in patients with sleep disorders. Sleep 1989; 12:487-494
8. Ray WA, Griffen MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262: 3303-3307
9. Doghramji K. The need for flexibility in dosing hypnotic agents. Sleep 2000;23(suppl 1):S16-S20
10. Greenblatt DJ. Benzodiazepine hypnotics: sorting the pharmacodynamic facts. J Clin Psychiatry 1991;52(9, suppl):4-10
11. Pagel JF. The treatment of insomnia. Am Earn Phys 1994;49:1417-1422
12. George CFP. Perspectives in the management of insomnia in patients with chronic respiratory disorders. Sleep 2000;23(suppl 1):S31-S35
13. Vermeeren A, Danjou PE, O'Hanlon JE Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol Clin Exp 1998; 13:S98-S107
14. Pagel JF, Zafralotfi S, Zammit G. How to prescribe a good nights sleep. Patient Care 1997 Feb;31(4):87-94
15. Kessler RC, McGonagle KC, Zhao S. Epidemiology of psychiatric disorders. Arch Gen Psychiatry 1994;51:8-19
16. Richardson GS. Managing insomnia in the primary care setting: raising the issues. Sleep 2000;23(suppl 1):S9-S12
17. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorder: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-418
18. Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo controlled trial in the Iowa driving simulator. Ann Intern Med 2000; 132:354-363
19. Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep 2000;23(suppl 1):S23-S30
20. Ware JC, Brown FW, Moorad PJ, et al. Effects on sleep: a double blind study comparing trimipramine to imipramine in depressed insomniac patients. Sleep 1989;12:537-549
21. Pagel JF. Disease, psychoactive medication, and sleep states. Primary Psychiatry 1996;3:47-51
22. Settle EC Jr. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998;59(suppl 16):25-30
23. Rickles K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo controlled trial. Br J Psychiatry 1994; 164: 802-805
24. Pagel JF. Pharmacologie alterations of sleep and dream: a clinical framework for utilizing the electrophysiological and sleep stage effects of psychoactive medications. Hum Psychopharmacol 1996;11:217-223
25. Fry JM. Current issues in the diagnosis and management of narcolepsy. Neurology 1998;50(2, suppl 1):S1-S48
26. McClellan KJ, Spencer CM. Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy. CNS Drugs 1998;9: 311-4324
27. Hauri. PJ. Current Concepts: The Sleep Disorders. Kalamazoo, Mich: Company; 1992
28. Harmann WM piddleton RK, Schott WJ. Drug treatment for sleep apnea. DICP Ann Pharmacother 1989;23:308-315
29. Hermann WS/1:' Development and critical evaluation of an objective procedure' for the electroencephalographic classification of psychotropic drugs. In: Hermelin. Electroencephalography in Drug Research. Stuttgart, Stuttgart, Germany Gustav. Fisher; 1982:385-445
30. Itil TM. The discovery of phsychotrophic drugs by computer-analyzed cerebral bioelectrical potennals (CEEG). Drug Dev Res 1981;1:373-407
31. Mamdema JW, Danhof M. Electroencephalogram effect measures and relationships between pharmacok and pharmacodynamics of centrally acting drugs. Clin Pharmacokinel 1992;23:191-215
32. Armitage R, Rochlen A, Fitch T, et al. Breâin recall and major depression: a preliminary report. Dreaming 1995;35:781-793
33. Kupfer DJ, Ehlers CL, Frean E, et al. Resistant effects of antidepressants: EEG sleep studies in depressed patients during: maintenance treatment. BiolPsychol 1994;35:781-793
34. Krakow B, Tandberg D, Barey M, et al. Nightmares disturbance in sexually assaulted women. Dreaming 1995 ;5:199-206 4
35. Pagel JF. Nightmares and disorders of dreaming. Am Fam Phys 2000;61 : 2037-2044
36. Pagel JF. Modeling drug actions on electrophysiologic effects produced by EEG modulated potentials. Hum Psychopharmacol 1993;8:211-216
37. Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996;100:333-337
38. Klauber GT. Clinical efficacy and safety of desmopressin in the treatment of nocturnal enuresis. J Pediatr 1989; 114(4, pt 2):719-722
39. Walters AS, for the International Restless Legs Syndrome Study Group. Toward a better definition of the restless leg syndrome. Mov Disord 1995;10:634-642
40. Lavigne GJ, Montplaisir JY. Restless leg syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994;17:739-743
41. Boghen D, Lamothe L, Elie R, et al. The treatment of restless leg syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci 1986; 13:245-247
42. Early CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless leg syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996;19:801-810
43. Walker SL, Fine A, Kryger MH. L-DOPA/carbidopa for nocturnal movement disorders in uremia. Sleep 1996;19:214-218
44. Stone BM, Turner C, Mills SL, et al. Hypnotic activity of melatonin. Sleep 2000;23:663-670
45. Arendt J, Middleton B, Stone B, et al. Complex effects of melatonin: evidence for photoperiodic responses in humans? Sleep 1999;2:625-636
46. Buxton OM, Copinschi G, Van Onderbergen A, et al. A benzodiazepine hypnotic facilitates adaptation of circadian rhythms and sleep-wake homeostasis to an eight hour delay shift simulating westwardjet lag. Sleep 2000;23:915-928